The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | TG-1701: a BTK inhibitor for B-cell malignancies
Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, discusses the Phase I trial (NCT03671590) assessing the safety and efficacy of the Burton’s tyrosine kinase (BTK) inhibitor TG-1701 in patients with relapsed/refractory (R/R) B-cell malignancies, including chronic lymphocytic leukemia (CLL). TG-1701 was evaluated as a monotherapy, or in combination with ublituximab and umbralisib (U2). The trial included a dose-escalation cohort and a dose-expansion cohort of specific B-cell malignancies, including CLL, Waldernström’s macroglobulinemia (WM), and mantle cell lymphoma (MCL). The combination of TG-1701 plus U2 showed promising clinical activity and enhanced depth of response over TG-1701 monotherapy with no additional toxicity. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
